Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS-0461 (PDC Therapeutics)
- Development stage
- Preclinical
- Lead developer
- PDC Therapeutics
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
RS-0461 is a preclinical-stage polymer-drug conjugate (PDC) being developed by PDC Therapeutics for the treatment of ovarian cancer. Utilizing a proprietary polymer-based delivery platform, RS-0461 is designed to function as a targeted chemotherapy, delivering a cytotoxic payload directly to tumor cells to enhance efficacy while reducing systemic toxicity. This approach is conceptually similar to antibody-drug conjugates (ADCs) but employs a synthetic polymer as the delivery vehicle instead of a monoclonal antibody. As of the current reporting, the specific molecular target and the identity of the chemotherapeutic payload remain undisclosed by the developer.
Beyond the preview
Go deeper on RS-0461 (PDC Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS-0461 (PDC Therapeutics).